Where Halda Therapeutics is establishing oral assets for lung and prostate cancer, the strategic deal offer from Johnson & Johnson, with its dedicated mission for its cancer sales by 2030, brings new hope for both companies for growth, business and development. Johnson & Johnson came up with an in-cash deal of $3.05 billion to acquire Halda Therapeutics to uplift and expand its cancer pipeline.
This deal will welcome Halda’s robust pipeline of oral therapies for curing solid tumors at J&J’s doorstep, based on Monday morning’s announcement. Halda’s key candidate is HLD-0915, an oral therapy to consume once a daily basis to treat prostate cancer that received a fast track designation from the legal body (FDA) in August.
In late 2024, the Phase 1/2 data were presented, which showed promising preliminary signs of anti-tumor activity. It showed the mitigation of prostate cancer biomarkers and accomplished the partial responses effectively in five out of five patients. Halda’s Phase 1/2 trial for metastatic, castration-resistant prostate cancer (mCRPC) is on the way.
J&J’s executive vice president of Innovative Medicine, Jennifer Taubert, said, “This strategic acquisition deal will recharge our deep oncology pipeline with a thrilling player asset in prostate cancer and a robust platform holding ability of curing various diseases and cancers, including oncology and beyond. Including delivering the potential mid-and long-term catalyst for growth.”
Halda also has the development platform named RIPTAC or Regulated Induced Proximity Targeting Chimera. Halda use this platform to design combined ligands that target two different proteins. One is a tumor-centric protein, and the other protein with a crucial function. The main focus is to eliminate tumor cells without disturbing non-cancerous healthy cells.
Halda represents all of its drugs with an RIPTACs tag, and other drugs lined up in the pipeline involve breast cancer drugs focusing on hormone receptor-positive (HR+) tumors. It’s a company’s asset qualified in different undisclosed and lunch cancer therapies.
For Halda, this deal is like a smooth return on investment. The company made its first appearance in the vast healthcare sector in 2019 out of the lab of Yale chemistry professor Craig Crews. After which, its excellence drew investors' attention consistently. The latest $126 raise accelerated HLD-0915, also an unnamed blank breast cancer asset is leading in the development race. For J&J, it’s a second crucial acquisition deal after its comprehensive buy-out of neuropsychiatric-focused Intra-Cellular Therapies worth $14.6 billion.
Mansi Kadam is a market research writer with over 3 years of experience analyzing trends in the healthcare industry. At Towards Healthcare, she covers innovations in medical sector, sustainability initiatives, and the evolving regulatory landscape.
